Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2012

View Archived Issues

Frontier Biotechnologies presents early clinical data for albuvirtide

Cubist Pharmaceuticals presents novel, broad-spectrum cephalosporin

New peptidase inhibitors patented by GlaxoSmithKline

Actelion Pharmaceuticals presents novel orexin receptor antagonists

New GPR119 receptor agonists patented by LG Life Sciences

Amgen synthesizes novel BACE inhibitors

Czech group presents novel NMDA receptor antagonists

Bristol-Myers Squibb discloses new HCV inhibitors

Results reported from phase II studies of BI-671800 in adult asthma

Hybrigenics begins phase II trial of oral inecalcitol in CLL

Immunetics awarded NIH contract for blood screening test

Galapagos presents promising in vivo results for GLPG-0492

Osmotica Pharmaceutical and Panacea Biotec form strategic alliance

e-Therapeutics begins second phase I trial of ETS-2101 in cancer

ReNeuron files two U.K. clinical trial applications and updates stem cell therapy pipeline

Oncolytics modifies phase III study of Reolysin

Visterra and Pfizer to collaborate on novel antibody discovery

KaloBios begins phase II study of MAb for asthma

Topline phase III data reported for rifamycin SV MMX

Healthpoint Biotherapeutics begins phase III trial for venous leg ulcers

FDA approves Genzyme's MS therapeutic

First launch of Eisai's antiepileptic agent announced in Europe

FDA accepts Otsuka's NDA resubmission

Sunesis plans to increase sample size in pivotal VALOR trial

Mitsubishi Tanabe seeks Japanese approval for Maintate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 4, 2025.
Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B
BioWorld
Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
Pharma execs speak out: UK pricing rebates scare investors
BioWorld
The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
ASCO 2025: Verastem has positive cancer data but stock sags
BioWorld
New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...